Sarepta Therapeutics

Founders James Summerton Marwan Fawaz

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 4
Average round size
info
The average size of a deal this fund participated in
$69M
Portfolio companies 4
Rounds per year 0.10
Lead investments 2
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Therapeutics
  • Genetics
  • Life Science
  • Information Technology
Summary

Sarepta Therapeutics appeared to be the Corporate Investor, which was created in 1980. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the Cambridge.

The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2018. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2019.

The current fund was established by Marwan Fawaz.

The standard case for the fund is to invest in rounds with 1 partaker. Despite the Sarepta Therapeutics, startups are often financed by Rev1 Ventures, Jain Foundation, GFB ONLUS.

The fund has exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biotechnology, Genetics. Among the various public portfolio startups of the fund, we may underline Lacerta Therapeutics, Myonexus Therapeutics

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sarepta Therapeutics:
Typical Co-investors
Sarepta Therapeutics is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sarepta Therapeutics:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allegiance Capital California, Huntington Beach, United States
Greenoaks Capital California, San Francisco, United States
Hanfor (Beijing) Capital Management Beijing, Beijing, China
HDI Global SE Germany, Saxony-Anhalt, Schönebeck (Elbe)
HT Ventures -
Huarong Xianfeng Zichan China, Guangdong, Shenzhen
Kibbutz Degania Bet -
Magnus Capital -
MedEdge -
Mercatus Capital Central, Central Region, Singapore
Normandie Business Angels Caen, France, Normandy
Pets.com California, Pasadena, United States
SamStella New York, New York, United States
Starquest Capital Beijing, Beijing, China
SVM Verwaltungsgesellschaft Germany, Hamburg
The Chartered Group Central, Central Region, Singapore
Torrent Gas Ahmedabad, Gujarat, India
Valence Capital Management New York, New York, United States
Wuhan Mutual Entertainment Cultural Industry Investment Management China, Hubei, Wuhan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

StrideBio

Biotechnology
Health Care
Information Technology
Therapeutics
$81M16 Mar 2021 Durham, North Carolina, United States

AavantiBio

Biotechnology
Genetics
Life Science
$107M22 Oct 2020 Cambridge, Massachusetts, United States

Lacerta Therapeutics

Biotechnology
Genetics
Therapeutics
$30M09 Aug 2018 Gainesville, Florida, United States

Myonexus Therapeutics

Biotechnology
Therapeutics
$60M08 May 2018 Columbus, Ohio, United States
News
StrideBio Closes $81.5M Series B Financing

– StrideBio, Inc. is a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies.
– The company closed a $81.5m Series B funding round.
Northpond Ventures and Novo Holdings A/S co-led the round with new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures joining existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sarepta Therapeutics?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: